1. Home
  2. KD vs TVTX Comparison

KD vs TVTX Comparison

Compare KD & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$13.18

Market Cap

2.8B

Sector

Technology

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$42.14

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KD
TVTX
Founded
2020
N/A
Country
United States
United States
Employees
80000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.8B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
KD
TVTX
Price
$13.18
$42.14
Analyst Decision
Buy
Buy
Analyst Count
5
11
Target Price
$31.00
$35.10
AVG Volume (30 Days)
3.1M
1.4M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
170.95
92.89
EPS
0.77
N/A
Revenue
$15,057,000,000.00
N/A
Revenue This Year
$3.73
$43.88
Revenue Next Year
$0.08
$33.16
P/E Ratio
$16.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.10
$13.88
52 Week High
$43.74
$42.13

Technical Indicators

Market Signals
Indicator
KD
TVTX
Relative Strength Index (RSI) 48.87 77.59
Support Level $12.07 $32.62
Resistance Level $13.81 N/A
Average True Range (ATR) 0.54 1.98
MACD 0.17 0.99
Stochastic Oscillator 68.50 100.00

Price Performance

Historical Comparison
KD
TVTX

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: